scholarly journals P311. No difference in immunogenicity of the original and biosimilar infliximab in patients with inflammatory bowel disease: short-term results

2016 ◽  
Vol 10 (suppl 1) ◽  
pp. S251.1-S251
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Short Term ◽  
Inflammatory Bowel

Preoperative biological therapy and short-term outcomes of abdominal surgery in patients with inflammatory bowel disease

Gut ◽  
2012 ◽  
Vol 62 (3) ◽  
pp. 387-394 ◽  
Author(s):  
Matti Waterman ◽  
Wei Xu ◽  
Amreen Dinani ◽  
A Hillary Steinhart ◽  
Kenneth Croitoru ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Abdominal Surgery ◽  
Bowel Disease ◽  
Biological Therapy ◽  
Short Term ◽  
Inflammatory Bowel

scholarly journals Mo1894 – Early Vedolizumab Trough Levels are Not Associated with a Short-Term Response in Patients with Inflammatory Bowel Disease

2019 ◽  
Vol 156 (6) ◽  
pp. S-877
Author(s):  
Karolina Pudilova ◽  
Dana Duricova ◽  
Martin Kolar ◽  
Karin Malickova ◽  
Veronika Hruba ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Short Term ◽  
Inflammatory Bowel ◽  
Trough Levels ◽  
Term Response

scholarly journals Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry

2019 ◽  
Author(s):  
María José Casanova ◽  
María Chaparro ◽  
Miguel Mínguez ◽  
Elena Ricart ◽  
Carlos Taxonera ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Combination Therapy ◽  
Adverse Events ◽  
Bowel Disease ◽  
Tumor Necrosis ◽  
Significant Proportion ◽  
Short Term ◽  
Loss Of Response ◽  
Inflammatory Bowel ◽  
Necrosis Factor

Abstract Background The effectiveness of the switch to another anti–tumor necrosis factor (anti-TNF) agent is not known. The aim of this study was to analyze the effectiveness and safety of treatment with a second and third anti-TNF drug after intolerance to or failure of a previous anti-TNF agent in inflammatory bowel disease (IBD) patients. Methods We included patients diagnosed with IBD from the ENEIDA registry who received another anti-TNF after intolerance to or failure of a prior anti-TNF agent. Results A total of 1122 patients were included. In the short term, remission was achieved in 55% of the patients with the second anti-TNF. The incidence of loss of response was 19% per patient-year with the second anti-TNF. Combination therapy (hazard ratio [HR], 2.4; 95% confidence interval [CI], 1.8–3; P < 0.0001) and ulcerative colitis vs Crohn’s disease (HR, 1.6; 95% CI, 1.1–2.1; P = 0.005) were associated with a higher probability of loss of response. Fifteen percent of the patients had adverse events, and 10% had to discontinue the second anti-TNF. Of the 71 patients who received a third anti-TNF, 55% achieved remission. The incidence of loss of response was 22% per patient-year with a third anti-TNF. Adverse events occurred in 7 patients (11%), but only 1 stopped the drug. Conclusions Approximately half of the patients who received a second anti-TNF achieved remission; nevertheless, a significant proportion of them subsequently lost response. Combination therapy and type of IBD were associated with loss of response. Remission was achieved in almost 50% of patients who received a third anti-TNF; nevertheless, a significant proportion of them subsequently lost response.

Early vedolizumab trough levels are not associated with short-term response in patients with inflammatory bowel disease

2019 ◽  
Vol 73 (1) ◽  
pp. 32-36
Author(s):  
Karolína Pudilová ◽  
Martin Kolář ◽  
Dana Ďuricová ◽  
Karin Malíčková ◽  
Veronika Hrubá ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Short Term ◽  
Inflammatory Bowel ◽  
Trough Levels ◽  
Term Response
Sign in / Sign up

Export Citation Format

Share Document